Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 01, 2015 8:31 AM ET


Company Overview of NovaRx Corporation

Company Overview

NovaRx Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of cell-based therapeutic vaccines for the treatment of cancer. Its products include Lucanix, a cell-based vaccine for the treatment of advanced stage non-small cell lung cancer; Glionix, a therapy for glioma (brain cancer); and a universal vaccine for patients with colon cancer, breast cancer, and prostate cancer. The company was founded in 1997 and is based in San Diego, California.

6828 Nancy Ridge Drive

Suite 100

San Diego, CA 92121

United States

Founded in 1997





Key Executives for NovaRx Corporation

Executive Chairman and Chief Executive Officer
Age: 42
Founder, Executive Vice Chairman and Chief Scientific Officer
Co-Founder and Director
Chief Financial Officer
Age: 51
Senior Vice President of Operations
Compensation as of Fiscal Year 2015.

NovaRx Corporation Key Developments

NovaRx Corporation Announces Results of Lucanix(R) Phase III Therapeutic Vaccine Trial

NovaRx Corporation announced results from the randomized Phase III trial of Lucanix(R) (belagenpumatucel-L) post-frontline maintenance therapy in non-small cell lung cancer. The primary endpoint of improving overall survival in 532 patients was not met primarily due to the inclusion of patients more than 12 weeks following the completion of frontline chemotherapy. In this predefined subgroup of 305 stage IIIB/IV patients, a median survival of 20.7 months was observed for Lucanix compared to 13.4 months for the control (HR 0.75). In a the predefined subgroup of these patients with a histology of squamous cell carcinoma a media survival of 20.7 months was observed for Lucanix compared to 12.3 months for the control (HR 0.58). In the predefined subgroup of these patients who received radiation therapy prior to enrollment a media survival of 40.1 months was observed for Lucanix compared to 10.3 months for the control (HR 0.45).

Similar Private Companies By Industry

Company Name Region
Aldevron, LLC United States
CIMA LABS INC. United States
Calico LLC United States
Newport Laboratories, Inc. United States
Cyrus Biotechnology, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NovaRx Corporation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at